An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas

International Journal of Dermatology

Volumn 41, Issue 11, 2002, Pages 804-809

  Tan, Mei Heng ^a   Meador, Stacie L ^a   Singer, Giselle ^a   Lebwohl, Mark G ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FACE DISORDER; GENERAL CONDITION IMPROVEMENT; HEALING; HUMAN; LONG TERM CARE; MAINTENANCE DRUG DOSE; MEDICAL ASSESSMENT; OINTMENT; OPEN STUDY; RECURRENT DISEASE; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; TELANGIECTASIA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; FACIAL DERMATOSES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036859884     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2002.01571.x     Document Type: Article

References (18)

1. Stoughton RB, Cornell RC. Corticosteroids. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine, 4th edn. New York, NY: McGraw-Hill, 1993: 2846-2850.
2. Aalto-Korte K. Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol 1995; 133 (2): 259-263.
3. Nielsen NV, Sorensen PN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol 1978; 114: 953-954.
4. Delescluse J, Van Der Endt JD. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Cutis 1996; 57 (Suppl.): 32-38.
5. Johnson M. Fluticasone propionate: Safety profile. Cutis 1996; 57 (Suppl.): 10-12.
6. Lebwohl M, Tan M-H, Meador S, Singer G. Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44 (1): 77-82.
7. Phillipps GH. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med 84 (Suppl. A): 19-23.
8. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990: 84 (Suppl. A): 25-29.
9. Van Der Meer JB, Coenraads PJ, Mulder PGH, Eggink HF. Efficacy and safety of treatment with fluticasone propionate ointment in the acute and maintenance treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 2): S107 (Abstract).
10. Spencer CM, Wiseman LR. Topical fluticasone propionate: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs 1997; 7: 318-334.
11. Chu AC, Munn S. Fluticasone propionate in the treatment of inflammatory dermatoses. Br J Clin Pract 1995; 49: 131-133.
12. Högger P, Rawert I, Rohdewald P. Dissolution, tissue binding and kinetics of receptor binding of inhaled glucocorticoids. Eur Respir J 1993; 6 (Suppl. 17): 584S (Abstract).
13. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061-1066.
14. Marshall RC, Du Vivier A. The effects on epidermal DNA synthesis of the butyrate esters of clobetasone and clobetasol, and the propionate ester of clobetasol. Br J Dermatol 1978; 98: 355-359.
15. Lehmann P, Zheng P, Lavker RM, Kligman AM. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983; 81: 169-176.
16. Dykes PJ, Marks R, Hill S, et al. The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Clin Exp Dermatol 1996; 21: 180-184.
17. Lee JY, Maibach HI. Corticosteroid skin atrophogenicity: Assessment methods. Skin Res Technol 1998; 4: 161-166.
18. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001; 7: 73-77.